Is there a Bearish outlook for Enzymotec Ltd (NASDAQ:ENZY) this week?


Press coverage about Enzymotec (NASDAQ:ENZY) has trended somewhat positive recently, Accern Sentiment reports. The stock was last seen 11.24% higher, reaching at $9.4 on August 1, 2017.

Following U.S. election volatility some analysts have updated their recommended target prices on shares of Enzymotec Ltd. (NASDAQ:ENZY). Therefore 67% are positive.

Enzymotec Ltd. has a 50 day moving average of 7.76 and a 200 day moving average of 8.35. It has underperformed by 6.69% the S&P500.

At the end of Mar reporting period, 5 institutional holders increased their position in Enzymotec Ltd. (NASDAQ:ENZY) by some 9,635 shares, 15 decreased positions by 384,888 and 10 held positions by 6,012,915. The Business's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.06 by $0.03.

On August 13 the company was upgraded to "Outperform" from "Market Perform" in a statement from Wells Fargo.

November 23 investment analysts at Jefferies maintained a company rating of "Hold" and moved down the price target to $7.00 from $11.00. The firm's market cap is $215.68 million. The Firm operates in two divisions: Nutrition segment and VAYA Pharma segment.

Timucuan Asset Management Inc Fl holds 9.72% of its portfolio in Hexcel Corporation for 2.14 million shares. Broad Run Investment Management Llc owns 2.86 million shares or 6.07% of their United States portfolio. Moreover, Ingalls & Snyder Llc has 4.03% invested in the company for 1.44 million shares. The stock's market capitalization is 184.34M.

Enzymotec (NASDAQ:ENZY) last issued its quarterly earnings data on Wednesday, May 17th. Renaissance Technologies LLC now owns 290,000 shares of the biotechnology company's stock valued at $1,900,000 after buying an additional 31,700 shares during the last quarter. Also, there are 0 buy, 1 sell and 0 strong sell ratings, collectively assigning a 3.33 average brokerage recommendation.

Receive Enzymotec Ltd. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. with's FREE daily email newsletter.



Related Posts

Surprising Growth for Apple, Even Before New iPhone
Apple sold 14% more iPads than the same time a year ago , breaking a 13-quarter streak of declining sales. Altogether, those purchases add up to $7.26 billion, up 22 percent since this time previous year .

Govt MP declines to discuss same-sex marriage
I'd rather talk about something else that actually matters to the Australian population. And so ended the world's shortest political interview.

IS claims responsibility for Herat mosque attack
The robotics team caught the world's attention after twice being denied visas to enter the USA for a competition. Jailani Farhad, a spokesman for the governor of Herat, also said that Mr.

Woman, two children held captive in Virginia home for two years
Carey said deputies went to a home in the 3600 block of Mine Road Saturday to check the welfare of a family. Carey told the Freelance Star in Fredericksburg that the woman is now hospitalized in serious condition.

United States urges Americans to leave North Korea before ban kicks in
Tillerson said the USA did not think of having a dialogue where the North Koreans come to the table assuming they are going to maintain their nuclear weapons is productive.

A 4.2 magnitude quake strikes OK
Several KOCO 5 viewers in central Oklahoma called to say they felt the natural disaster . Officials reported that power had been restored to both substations by 11:05 p.m.

Eichel, Sabres negotiating potential 8-year deal
If a report that surfaced Wednesday is accurate, Jack Eichel could be a member of the Buffalo Sabres well into the 2020s. He led the team with 57 points and finished second with 24 goals in 2016-17 despite being limited to 61 games.

Statoil ASA (STO) Receiving Somewhat Positive News Coverage, Accern Reports
Scotiabank reissued a "hold" rating and set a $17.00 price objective on shares of Statoil ASA in a report on Thursday, July 13th. The oil and gas company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.13.

USA tests ICBM amid latest North Korea provocation
The ejection test was carried out on land at Sinpo Naval Shipyard on Sunday, the United States defense official told CNN. Meanwhile, a senior Republican senator said President Trump considered going to war with North Korea as an option.

Messi farewells Neymar as PSG deal nears
FFP was implemented by European football's governing body UEFA in an attempt to prevent reckless spending by clubs and to increase competition.

© 2015 ExpressNewsline. All Rights reserved.